Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment (HOBBIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04091542
Recruitment Status : Recruiting
First Posted : September 16, 2019
Last Update Posted : September 16, 2019
Sponsor:
Information provided by (Responsible Party):
University Hospital, Ghent

Brief Summary:

With the HOBBIT trial, the investigators want to develop a technology that allows volunteers to hold their breath for a long time. This technique will then be taught to patients with breast cancer to be able to hold their breath long-term during the irradiation. After all, research has shown that the heart is in a better position when the patient enters her breath after a deep inhalation, as a result of which there is less unwanted radiation of the heart. To develop this technique the investigators use healthy volunteers, who are asked several times to hold their breath as long as comfortable. Before the respiratory arrest the investigators allow these volunteers to hyperventilate, administer oxygen and cause hyperinflation of the lungs.

The volunteers come back four times, on four consecutive days. The first day they receive a short training. Afterwards oxygen is administered for a few minutes while the volunteers are asked to hyperventilate. Afterwards, by using the learned technique, they must hold their breath for as long as possible, comfortably. They should hold their breath 3 times in total with a short break in between. The following days there is always a change in the preparation protocol, compared to the previous study. Different parameters in the protocol will be changed for different groups of volunteers, this is based on randomization. In this way the effect of different parameters in the preparation of the AHS can be investigated. The investigators will use this information to develop a new protocol for extending the duration of breathing to two minutes and thirty seconds for use during radiotherapy treatment. The method for finding the optimal technique is iterative optimization. This method follows a process of development, testing, feedback and redevelopment cycles. Iteratively, these cycles of development use the prior research to further elaborate the most promising discoveries and drop paths that do not produce the desired result. During the development The investigators listen to the input of different people: doctors, nurses, support staff, engineers and the participants, to guarantee the usability of the technique on the radiotherapy device. Once the researchers think they have found a solution that meets all the conditions, a group of untrained volunteers are asked to implement the technique. With this the investigators validate the technique for later use in breast cancer patients.


Condition or disease Intervention/treatment Phase
Breast Cancer Device: Optiflow/Ventilator Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment (HOBBIT): Development of Support Technique to Prolong Breath Hold Time During Radiotherapy
Actual Study Start Date : March 15, 2019
Estimated Primary Completion Date : May 15, 2020
Estimated Study Completion Date : October 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: FiO2 group 1
FiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.

Experimental: FiO2 group 2
FiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.

Experimental: Duration 1
In duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.

Experimental: Duration 2
In duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.

Experimental: respiratory rate 1
In the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.

Experimental: respiratory rate 2
In the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.

Experimental: Position 1
The position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.

Experimental: Position 2
The position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
Device: Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.




Primary Outcome Measures :
  1. conditions for a technique for L-DIBHs of more than two minutes thirty seconds [ Time Frame: 2 years ]
    duration of preparation/hyperventilation and oxygenation


Secondary Outcome Measures :
  1. Oxygen saturation [ Time Frame: 1 year ]
    fraction of [oxygen]-saturated hemoglobin relative to total hemoglobin in the blood

  2. heart rate [ Time Frame: 1 year ]
    speed of the heartbeat measured by the number of contractions (beats) of the heart per minute (bpm)

  3. diastolic and systolic blood pressure [ Time Frame: 1 year ]
    the pressure of circulating blood on the walls of blood vessels

  4. EtCO2 [ Time Frame: 1 year ]
    patient's end-tidal CO2

  5. average L-DIBH time [ Time Frame: 1 year ]
    measured in minutes and seconds

  6. average time needed for SpO2 to recover to normal [ Time Frame: 1 year ]
    measured in minutes and seconds

  7. average total time needed to perform three L-DIBHs consequently [ Time Frame: 1 year ]
    measured in minutes and seconds

  8. Measurement of linear anteroposterior displacement [ Time Frame: 1 year ]
    measured in millimetres

  9. dizziness [ Time Frame: 1 year ]
    an impairment in spatial perception and stability.

  10. fear [ Time Frame: 1 year ]
    a feeling induced by perceived danger or threat that occurs in certain types of organisms, which causes a change in metabolic and organ functions and ultimately a change in behavior, such as fleeing, hiding, or freezing from perceived traumatic events

  11. headache [ Time Frame: 1 year ]
    the symptom of pain anywhere in the region of the head or neck

  12. syncope [ Time Frame: 1 year ]
    syncope

  13. coughing [ Time Frame: 1 year ]
    a sudden, and often repetitively occurring, protective reflex which helps to clear the large breathing passages from fluids, irritants, foreign particles and microbes

  14. dyspnea [ Time Frame: 1 year ]
    the feeling that one cannot breathe well enough

  15. nausea [ Time Frame: 1 year ]
    an unpleasant, diffuse sensation of unease and discomfort, often perceived as an urge to vomit

  16. vomiting [ Time Frame: 1 year ]
    the involuntary, forceful expulsion of the contents of one's stomach through the mouth and sometimes the nose

  17. itching [ Time Frame: 1 year ]
    a sensation that causes the desire or reflex to scratch

  18. pain [ Time Frame: 1 year ]
    a distressing feeling often caused by intense or damaging stimuli

  19. palpitations [ Time Frame: 1 year ]
    the perceived abnormality of the heartbeat characterized by awareness of cardiac muscle contractions in the chest, which is further characterized by the hard, fast and/or irregular beatings of the heart

  20. blurred vision [ Time Frame: 1 year ]
    an ocular symptom

  21. muscle cramps [ Time Frame: 1 year ]
    a sudden, involuntary muscle contraction or over-shortening; while generally temporary and non-damaging, they can cause significant pain, and a paralysis-like immobility of the affected muscle



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female
  • Volunteer
  • Age ≥ 18 years
  • Karnofsky index of at least 90
  • Single DIBH of at least twenty seconds without assistance
  • Informed consent obtained, signed and dated before specific protocol procedures

Exclusion Criteria:

  • Pregnant women
  • Volunteers above WHO Obesity class II (BMI>35kg/m²)
  • Subjects on oxygen treatment during day or night
  • COPD or Asthma patients
  • Volunteers with pulmonary hypertension
  • New York Heart Association functional classification (NYHA) of 2 or less
  • Personal history of cerebrovascular disease, aortic disease, coronary artery disease or myocardial disease
  • Treatment with antihypertensive medication
  • Missing more than three teeth without use of a prosthesis
  • Gastric tube present
  • Smoking
  • Previous breath-holding experience (e.g. diver, etc.)
  • Anxiety symptoms grade 1 or higher according to CTCAE v.5
  • Mental condition rendering the volunteer unable to understand the nature, scope and possible consequences of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04091542


Contacts
Layout table for location contacts
Contact: Vincent Vakaet, drs 093323956 vincent.vakaet@ugent.be
Contact: Hans Van Hulle, drs 0471662832 hans.vanhulle@ugent.be

Locations
Layout table for location information
Belgium
University Hospital - Radiotherapy Department Recruiting
Ghent, Belgium, 9000
Contact: Liv Veldeman, MD, PhD       liv.veldeman@uzgent.be   
Contact: Vincent Vakaet, MD       vincent.vakaet@uzgent.be   
Principal Investigator: Liv Veldeman, MD, PhD         
Sub-Investigator: Wilfried De Neve, MD, PhD         
Sub-Investigator: Vincent Vakaet, MD         
Sub-Investigator: Hans Van Hulle, MA         
Sponsors and Collaborators
University Hospital, Ghent
Investigators
Layout table for investigator information
Principal Investigator: Liv Veldeman, dr University of Ghent

Layout table for additonal information
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT04091542     History of Changes
Other Study ID Numbers: EC2019/0127
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: September 16, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Ghent:
breath hold
hyperventilation
oxygenation
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Hyperventilation
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms